INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

AGIOAGIOS PHARMACEUTICALS, INC.

CIK 0001439222

EDGAR filingsOpen in network
Disclosed transactions11
Buys / sells2 / 3
Max Insider Score28
Connections5with evidence

AGIO · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
7
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
7,866 sh
Oct 26, 2026Oct 28, 2026
traded Oct 26, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Gheuens SarahChief Medical Officer · Oct 23, 2026
  • ← Disclosed trade inevidence
    Gilbert Ray Cisneros, Jr.Purchase disclosed 2026-09-10 · Sep 10, 2026
  • ← Lobbied forevidence
    GRIDIRON PUBLIC AFFAIRS, LLCLDA Q2 2026 second quarter · Health issues · Aug 26, 2026
11
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL
$296K
7,866 sh
Oct 26, 2026
Oct 28, 2026
traded Oct 26, 2026
+2d
SEC FORM 4

Evidence

2
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$197K
7,866 sh
Oct 26, 2026Oct 28, 2026
traded Oct 26, 2026
+2dSEC FORM 4

Evidence

8
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$56K
1,489 sh
Oct 21, 2026Oct 23, 2026
traded Oct 21, 2026
+2dSEC FORM 4

Evidence

0
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$13K
500 sh
Oct 22, 2026Oct 23, 2026
traded Oct 22, 2026
+1dSEC FORM 4

Evidence

0
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
500 sh
Oct 22, 2026Oct 23, 2026
traded Oct 22, 2026
+1dSEC FORM 4

Evidence

1
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$19K
500 sh
Oct 22, 2026Oct 23, 2026
traded Oct 22, 2026
+1dSEC FORM 4

Evidence

3
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
1,489 sh
Oct 21, 2026Oct 23, 2026
traded Oct 21, 2026
+2dSEC FORM 4

Evidence

0
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$37K
1,489 sh
Oct 21, 2026Oct 23, 2026
traded Oct 21, 2026
+2dSEC FORM 4

Evidence

20
Gilbert Ray Cisneros, Jr.DSelf
AGIOAGIOS PHARMACEUTICALS, INC.
Purchase
BUY$1,001 – $15KAug 20, 2026Sep 10, 2026
traded Aug 20, 2026
+21dHOUSE PTR

Evidence

28
Gilbert Ray Cisneros, Jr.DSelf
AGIOAGIOS PHARMACEUTICALS, INC.
Purchase
BUY$1,001 – $15KMar 3, 2026Apr 7, 2026
traded Mar 3, 2026
+35dHOUSE PTR

Evidence

  • ← Lobbied forevidence
    JEFFREY J. KIMBELL & ASSOCIATES, INC.LDA Q1 2026 first quarter · Health issues · Aug 26, 2026

    • Lobbying

    $100K reported · de-duplicated
    2026 Q2 $30K in-house2026 Q1 $70K in-house
    • GRIDIRON PUBLIC AFFAIRS, LLC—2026 Q2 · posted Aug 26, 2026 · Health issues
    • JEFFREY J. KIMBELL & ASSOCIATES, INC.$10K2026 Q1 · posted Aug 26, 2026 · Health issues
    • JEFFREY J. KIMBELL & ASSOCIATES, INC.$10K2026 Q2 · posted Aug 26, 2026 · Health issues
    • In-house report$70K2026 Q1 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid
    • GRIDIRON PUBLIC AFFAIRS, LLC$10K2026 Q2 · posted Aug 26, 2026 · Health issues
    • In-house report$30K2026 Q2 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.